Akebia Therapeutics, Inc. (AKBA) is a publicly traded Healthcare sector company. As of July 27, 2026, AKBA trades at $1.22 with a market cap of $327.28M and a P/E ratio of -15.25. AKBA moved +0.41% today. Year to date, AKBA is -23.27%; over the trailing twelve months it is -68.23%. Its 52-week range spans $0.82 to $4.08. Analyst consensus is buy with an average price target of $6.00. Rallies surfaces AKBA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for AKBA combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $1.22 |
| Market Cap | $327.28M |
| P/E Ratio | -15.25 |
| EPS | $-0.08 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.08 |
| 52-Week Low | $0.82 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $232.40M |
| Net Income | $-20.51M |
| Gross Margin | 81.01% |
1 analysts cover AKBA: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $6.00.